Abstract: Provided are compositions and methods for cleaving a DNA sequence in a cell. The methods involve comprising introducing into a cell a recombinant vector containing a clustered regularly interspaced short palindromic repeats (CRISPR) system. The system includes a CRISPR RNA (crRNA) targeted to a DNA sequence in the cell that is operatively linked to a promoter; and CRISPR-associated enzymes (Cas) 10, Cas6, and at least one Csm protein. The Cas 10 cleaves the DNA sequence only during transcription of the DNA sequence that is operatively linked to the promoter. Also provided are recombinant vectors for modifying cells, cells that contain the recombinant vectors and modifications introduced by them, and kits that include the modified vectors.

Abstract: A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and/or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-?, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors.

Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.

Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.

Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.

Abstract: Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells.

Abstract: An imaging signal extraction apparatus comprising: an interface; a processing device, the processing device operatively coupled to the interface; and a computer readable medium comprising instructions that, when executed by the processing device, perform operations comprising: a) generating a two-dimensional image from imaging information obtained from the interface, thereby estimating ballistic component of the imaging information; b) generating a three-dimensional image by remapping the two-dimensional image; c) identifying a candidate object in the three-dimensional image; d) obtaining an estimated spatial forward model of the candidate object by mapping the three-dimensional image of the candidate object with a point-spread-function associated with the imaging apparatus; e) obtaining background-corrected data by using the estimated spatial forward model of the candidate object and estimated temporal components; and f) iteratively updating the estimated spatial forward model and estimated temporal componen

Abstract: Compounds of formula: are useful as antitumor agents. In these compounds, R10 is (a) (C1-C10) hydrocarbyl, (C1-C10)halohydrocarbyl, (C1-C6)hydroxyalkyl, or or R10 is (b) in which Q and A are linkers and Ar is optionally substituted monocyclic or bicyclic aryl or heteroaryl.

Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acintobacter lysin polypeptides.

Abstract: This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.

Abstract: A standardized, quantitative risk assessment method and apparatus for noninvasive melanoma screening. The apparatus and methods generate a melanoma Q-Score which calculates and displays a probability that a skin lesion is melanoma.

Abstract: 1-Phenylacetyl-8-aminohexahydro-2H-pyrano[3,4-b]pyrazines of formula are disclosed. The compounds are kappa ligands and are useful to treat drug dependency, pruritus, pain, and inflammation.

Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods.

Abstract: 1-Phenylacetyl-8-aminohexahydro-2H-pyrano[3,4-b]pyrazines of formula are disclosed. The compounds are kappa ligands and are useful to treat drug dependency, pruritus, pain, and inflammation.

Abstract: 1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.

Abstract: The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant S. aureus (MRSA) and vancomycin intermediate S. aureus (VISA).

Abstract: The present invention relates to immunogenic immune complexes, related compositions, and related methods.

Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.

Abstract: Methods and compositions are provided for translational profiling and molecular phenotyping of specific tissues, cells and cell subtypes of interest. The methods provided herein facilitate the analysis of gene expression in the selected subset present within a heterogeneous sample.

Abstract: Processes to identify variants that affect biochemical regulation are described. Generally, models are used to identify variants that affect biochemical regulation, which can be used in several downstream applications. A pathogenicity of identified variants is also determined in some instances, which can also be used in several. Various methods further develop research tools, perform diagnostics, and treat individuals based on identified variants.